CN1782077A - HAb18Gedomab 1 monoclonal antibody and its light and heavy chain variable area genes, coding polypeptide and use - Google Patents
HAb18Gedomab 1 monoclonal antibody and its light and heavy chain variable area genes, coding polypeptide and use Download PDFInfo
- Publication number
- CN1782077A CN1782077A CN 200410078858 CN200410078858A CN1782077A CN 1782077 A CN1782077 A CN 1782077A CN 200410078858 CN200410078858 CN 200410078858 CN 200410078858 A CN200410078858 A CN 200410078858A CN 1782077 A CN1782077 A CN 1782077A
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- antibody
- chain variable
- heavy chain
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The present invention immunizes mouse with HAb18G/CD147 extra-cellular region protein to prepare specific hybrid tumor cell strain HAb18Gedomab1, obtain monoclonal antibody HAb18Gedomab1, which can combine specifically to HAb18G/CD147 expressed effectively in human liver fibrosis tissue and liver stellate cell and possesses functions of promoting MMPs secretion and degrades extra-cellular matrix. The antibody may be used in preparing medicine for reversing liver fibrosis and other matrix deposition related diseases. The present invention clones the light and heavy chain variable area genes successively. Several forms of small molecular gene engineering antibody are constituted and expressed based on the genes and gene engineering method, and the polypeptide coded based on the genes is cross-linked with several effect factors, so as to prepare medicine for reversing liver fibrosis and other matrix deposition related diseases.
Description
Technical field
The present invention relates to biotechnology and cell engineering field, particularly monoclonal antibody HAb18Gedomab1 and heavy chain thereof, chain variable region gene, by the application of the polypeptide of described genes encoding and above-mentioned monoclonal antibody and light, heavy chain variable region gene, polypeptide.
Background technology
Hepatic fibrosis is various chronic hepatopathys to the common pathological change of liver cirrhosis development and must be through approach.Chronic hepatopathy mainly comprises various viral hepatitis, especially hepatitis C and hepatitis B.Whole world HbsAg carrier surpasses 2.8 hundred million.China is the high popular district of hepatitis B, its HbsAg carrier 1.3 hundred million, and hepatitis B patient surpasses 3,000 ten thousand, has the hepatitis B patient of 25-40% to cause liver cirrhosis, liver cancer, and its death toll was 400,000 people/years, had become China's serious social concern.Therefore control and reverse hepatic fibrosis become the key link that reduces liver problem sufferer's mortality ratio.Various chronic hepatopathys at first cause hepatic fibrosis, develop into liver cirrhosis then.Based on the application of Ultrastructural research of liver in recent years and molecular biotechnology, anthropogenetic hepatic fibrosis and even liver cirrhosis can reverse fully.Late international hepatopathy expert Hans Popper once asserted " who can stop hepatic fibrosis, and who just can cure most of hepatopathys ".
Liver cancer related antigen HAb18G is a kind of membrane protein molecule of high glycosylation.Anti-human monoclonal antibodies HAb18 by the preparation of my chamber oneself screens from liver cancer cDNA library and has obtained its cDNA sequence, inquiry Genbank confirms that itself and CD147 molecule cDNA sequence open reading frame are in full accord, with matrix metalloproteinase inductor EMMPRIN (Extrcellular Matrix metalloproteinase Inducer), Basigin etc. be same molecule.Functional study shows that HAb18G/CD147 can stimulate the human fibroblasts to secrete three kinds of proteolytic enzyme, degraded basilar membrane and intercellular substance.Known, HAb18G/CD147 is high expression level in the fibrosis tissue, especially the most remarkable with the hepatic fibrosis tissue expression, it is positioned the bile duct epithelial cell of breeding in liver cell and the hepatic fibrosis matrix, the equal high expression level of HAb18G/CD147 in the hepatic fibrosis pathology that HCV (hepatitis C virus), AIH (autoimmune hepatitis), HBV (hepatitis B virus), PBC (primary biliary cirrhosis) cause.These characteristics demonstrate this molecule and played the part of important role in the pathology processes of hepatic fibrosis, and it may MMPs be relevant with stimulating hepatic parenchymal cells, hepatic stellate cell secretion.
MMPs has the effect of ECM compositions such as each Collagen Type VI of degraded, proteoglycan, TIMPs is a MMPs specific tissue supressor, transcribing with active of TIMPs and MMPs can be subjected to multifactor and multilevel adjusting in the body, if the balance disorder then corresponding pathological state can occur.Many scholars find, expression amount and active decline of MMPs in the model of the hepatic fibrosis of the mankind's chronic hepatopathy and mouse, have all been observed, and the expression of TIMPs significantly increases, and in the whole process of hepatic fibrosis development, continue to exist, the over-deposit of prompting liver matrix is the main pathological characters of hepatic fibrosis progress.And in the decubation of hepatic fibrosis, with the feature that reverts to of the degraded of fibrous matrix and normal liver tissue.
The therapeutic advance of current hepatic fibrosis is: alleviate Fibrotic degree, delay of progression reverses the pathology process, but does not still have specific treatment means at hepatic fibrosis itself.As the peptide receptoroid antagonist of transforminggrowthfactor-(TGF-β 1),, can cause the undesirable actions such as degeneration of autoimmune disorder and cell after the use because its acceptor extensively is present in the various types of cells.Other as endothelin-receptor antagonists, prolyl hydroxylase inhibitors etc. all research among, the pharmacodynamic result that Shang Weiyou is clear and definite.
Summary of the invention
One object of the present invention is to prepare the monoclonal antibody HAb18Gedomab1 at the HAb18G/CD147 extracellular region of high specific, and monoclonal antibody HAb18Gedomab1 heavy chain and chain variable region gene and encoded polypeptide product thereof are provided.
Another object of the present invention is with above-mentioned HAb18Gedomab1 monoclonal antibody or its heavy chain and chain variable region gene or encoded polypeptide, perhaps reassemble into genetic engineering antibody, antibody fusion protein or protein conjugate, the derivative etc. of various ways, be used to reverse the medicine of apposition relative diseases such as hepatic fibrosis.
According to an aspect of the present invention, the preparation, evaluation, the purifying that relate to monoclonal antibody HAb18Gedomab1.The present invention is an immunogen with the extracellular region protein of the HAb18G/CD147 of high expression level in the hepatic fibrosis tissue, adopts the hybridoma technology preparation and filters out hybridoma cell strain HAb18Gedomab1 (on May 31st, the 2004 Chinese typical culture collection center accession designation number: CCTCC-C200408) of stably excreting mouse-anti people HAb18Gedomab1 monoclonal antibody.To collect ascites behind its inoculation homology mouse peritoneal.Adopt in method pair cell culture supernatant such as flow cytometry, immunohistochemical methods and the ascites excretory specific antibody to carry out affinity and identify, its result shows that HAb18Gedomab1 organizes all with people's stellate cell (HSCs) and people's hepatic fibrosis and combines.Gained ascites obtains the HAb18Gedomab1 monoclonal antibody of certain purity through the ion exchange chromatography purifying.
According to another aspect of the present invention, the clone who relates to monoclonal antibody HAb18Gedomab1 heavy chain and chain variable region gene.The present invention uses the PCR primer of an Analysis of Nested Design, has successfully cloned light, the heavy chain variable region gene of this antibody from hybridoma cell strain HAb18Gedomab1.Wherein said heavy chain variable region gene total length is 336bp, its nucleotide sequence as in the sequence table＜400〉1 shown in, its amino acid sequence coded as in the sequence table＜400〉3 shown in.Described chain variable region gene total length is 324bp, its nucleotide sequence as in the sequence table＜400〉2 shown in, its amino acid sequence coded as in the sequence table＜400〉4 shown in, confirm the mouse antibodies variable region that the equal codified of resulting heavy chain and chain variable region gene is correct by analysis.
Description of drawings
Fig. 1 is the karyotype figure of hybridoma cell strain HAb18Gedomab1.
Fig. 2 is that the SDS-PAGE purity of monoclonal antibody HAb18Gedomab1 is identified figure.
Fig. 3 is light for the monoclonal antibody HAb18Gedomab1 for the RT-PCR amplification, the agarose gel electrophoresis figure of heavy chain variable region gene.
Fig. 4 is the order-checking collection of illustrative plates of monoclonal antibody HAb18Gedomab1 heavy chain variable region gene.
Fig. 5 is the order-checking collection of illustrative plates of monoclonal antibody HAb18Gedomab1 chain variable region gene.
Fig. 6 is the gelatinase spectrogram of monoclonal antibody HAb18Gedomab1.
Fig. 7 is the type i collagen zymogram figure of monoclonal antibody HAb18Gedomab1.
Fig. 8 wears theca cell figure for reorganization basement membrane degradation experiment.
Embodiment
1, the preparation of monoclonal antibody HAb18Gedomab1 and evaluation.
Immunization method: get the heavy female BALB/C mice in the 18g left and right sides (this school animal center provides) in 8～10 ages in week, with the HAb18G/CD147 extracellular region protein is immunogenic, carry out routine immunization, adopt subcutaneous multi-point injection, 100 μ g/ only add incomplete freund adjuvant booster immunization every 2 weeks with same dose antigen, abdominal injection, detect how anti-tiring of mice serum before the cytogamy, high person's tail vein supplementary immunization 1 time again of tiring, dosage is the same.The myeloma cell line SP2/0 that after 3 days HAb18C/CD147 extracellular region protein mice immunized splenocyte and interior generation is obtained merges under the PEG-1000 effect with 5: 1 ratio, and fused cell is cultivated in the HAT selective medium.
The foundation of hybridoma cell strain: with HAb18G/CD147 extracellular region protein antigen, the indirect ELISA method screening positive clone is behind the continuous limiting dilution in positive hole 2～3 times.A large amount of amplifications and liquid nitrogen cryopreservation; Give the hybridoma of homology mouse peritoneal injection inoculation screening simultaneously, collect ascites behind 10～14d.Described HAb18Gedomab1 hybridoma cell strain karyomit(e) is at 58-126, mode 104-126, and referring to accompanying drawing 1, its secretion specific monoclonal antibody HAb18Gedomab1.
Monoclonal antibody is identified: the situation that combines that further detects Hybridoma Cell Culture supernatant and ascites and people's stellate cell (HSCs-T6) film surface antigen with flow cytometry FACS; The SP immunohistochemical method detects HAb18Gedomab1 ascites and combines with the specificity of people's hepatic fibrosis tissue; The mensuration of hybridoma cell strain HAb18Gedomab1 culture supernatant and mouse ascites antibody titers.Hypotype is accredited as mouse IgG1.
The purification process of monoclonal antibody HAb18Gedomab1: adopt cation exchange chromatography, promptly the SP Sepharose of FPLC system FF ion exchange chromatography carries out purifying to the crude extract of HAb18Gedomab1 ascites.Elutriant A liquid: 0.02mol/L citrate buffer solution (pH5.4), B liquid: 0.02mol/L citrate buffer solution, 1mol/L sodium-chlor (pH5.4).Flow velocity 1ml/min.
The evaluation of target protein behind the purifying: adopt ELISA method and non-reduced polyacrylamide gel electrophoresis, concentrate gum concentration 5%, resolving gel concentration 10%, electrophoretic buffer is the Tris-glycine buffer of PH8.3, referring to accompanying drawing 2,1 is 200KD Marker among the figure, and 2 is HAb18Gedomab1 ascites, 3 for passing the peak, and 4 are elution peak (being the monoclonal antibody HAb18Gedomab1 of purifying).
2, the clone of light, the heavy chain variable region gene of monoclonal antibody HAb18Gedomab1, analyze and recombinate.
Used cell strain is stably excreting monoclonal antibody HAb18Gedomab1 hybridoma cell strain HAb18Gedomab1, and its excretory antibody molecule hypotype is IgG1.
The clone of the variable region gene of anti-HAb18G/CD147 extracellular region protein monoclonal antibody HAb18Gedomab1
Get the HAb18Gedomab1 hybridoma (5 * 10 that is in logarithmic phase
6), adopt the guanidinium isothiocyanate single stage method to extract total RNA, take a morsel and carry out the quantitative and 1% denaturing formaldehyde agarose gel electrophoresis detection of ultraviolet spectrophotometer.Be random primer with Oligo (dT) 15 (Promega company) subsequently, cDNA first chain is synthesized in reverse transcription.Then, utilize above-mentioned pairing primer extension product Fd (about 736bp) and full-length light chains (about 731bp) behind LMP sepharose (1.5%) electrophoresis, cut glue and separate the target fragment.Behind gel-purified test kit (promega Inc) recovery purifying, gel electrophoresis identifies that referring to accompanying drawing 3, M is DL-2000Marker among the figure, and 1 is the HAb18Gedomab1 heavy chain variable region gene, and 2 is the HAb18Gedomab1 chain variable region gene.Afterwards with the purpose fragment cloning to the T carrier, sequencing analysis is referring to accompanying drawing 4,5.
Oligo (dT)
15(Promega company) is as follows for the reverse transcription scheme of random primer: add the total RNA of 1 μ g (2 μ L) in the 20 μ L reaction systems successively, 0.5ug random primer Oligo (dT)
15(1 μ L), 4ulMgCL
2(25mM) 2 μ L, 5 * dNTPs, 2 μ L, 10 * damping fluid, 0.5 μ L RNase inhibitor adds ThermoScript II AMV 15U (0.75 μ L), water is mended to 20 μ L, mixing, 42 ℃ of water-bath 1h boil 3min, reaction product place-20 ℃ standby.
The pcr amplification reflection is carried out according to a conventional method: with above-mentioned product is template, uses 1 counterweight strand primer and 1 pair of light, heavy chain variable region gene of light chain primer amplification antibody respectively.Reaction system is: template cDNA2.5ul, dNTP (each 0.4mM), 10 * Buffer 5ul, Ex Taq archaeal dna polymerase 1.25u, 5 ' end and 3 ' end each 5ul of primer (about 30pmol) add water to 50ul, mixing, instantaneous centrifugal after, add 1-2 drop of liquid paraffin, put on the PCR instrument and react.Reaction conditions: 94 ℃ of 1min, 54 ℃ of 1min, 72 ℃ of 1min, 35 circulations, last 72 ℃ are extended 10min.
Purpose fragment T carrier cloning order-checking scheme is as follows: with reclaiming after the PCR product gel electrophoretic separation, be connected into the pMD18-T carrier.The ligation system is: pMD18-T carrier 1ul, PCR product gel purifying heavy chain (or light chain) 3ul, deionized water 1ul, connect damping fluid 5ul, 4 ℃ are spent the night behind the mixing, transformed into escherichia coli JM109, the screening recombinant clone adopts the order-checking of universal sequencing primer thing then.
The HAb18Gedomab1 monoclonal antibody variable region gene pcr amplification primer sequence of design is as follows:
Murine heavy chain V district 5 ' end primer
5’-GGGGATATCCACCATGTACTTGGGACTGAACTGTGT-3’
Murine heavy chain V district 3 ' end primer
5’-AGGCTTACTAGTACAATCCCTGGGCACAAT-3’
Mouse light chain V district 5 ' end draws
5’-GGGGATATCCACCATGGACACACAGACTCAGGTCTTTATA-3’
Mouse light chain V district 3 ' end primer
5’-GCGCCGTCTAGAATTAACACTCATTCCTGTTGAA-3
Sequential analysis shows, its VH gene and the IG germline gene HV6 IGHV6S1*01 of family dna homolog are the highest, the mouse monoclonal antibody gene M MMABIP1H (NCBI:Y08908) of its Fd gene and anti-birch pollen allergen and the mouse monoclonal antibody gene VH10G1 homology the highest (NCBI:AB050074) of anti-dsRNA.The IGKV6-20*01 dna homolog of its VL gene and IG germline gene KV6 family is the highest.The mouse single-chain antibody gene (NCBI:MMU68543) of its Lc gene and anti-foot-and-mouth disease virus and the mouse monoclonal antibody dna homolog the highest (NCBI:AF466699) of anti-anti-YGNNV.This explanation, resulting heavy chain and chain variable region gene are the gene of the correct mouse antibodies variable region of codified.
, heavy chain variable region gene light or polypeptide product based on above-mentioned anti-hepatic fibrosis monoclonal antibody HAb18Gedomab1 of being cloned into, adopt gene engineering method, can be built into the genetic engineering antibody medicine of various ways, also can reconstitute the fusion or the recombinant protein medicine of various ways, can be crosslinked the active proenzyme that changes of adjusted extracellular matrix or biological response modifier etc. as prodrug, to be used to reverse the experimental study and the clinical application of apposition relative disease such as hepatic fibrosis.
From light, heavy chain variable region gene of the present invention, the novel antibody that can reassemble into mainly contains following several form: (1) chimeric antibody.Be that C district with the V district of mouse MAb and people Ig is formed by connecting and is people-mouse chimeric antibody.Specificity and avidity that it has intactly kept mouse MAb have reduced untoward reactions such as HAMA simultaneously.(2) humanized antibody.Humanization modified at the variable region gene structure, comprise that CDR transplants, surface amino groups acid residue frosting, the exchange of skeleton district, the location keeps and the epi-position guiding is selected etc., thereby the mouse source property that has not only reduced the variable region has kept specificity and the avidity of mouse MAb simultaneously again.(3) small molecular antibody.Mainly contain by VH-CH1 and VL-C1 form Fab antibody, with a polypeptide (GLy4Ser)
3The single domain antibody that joint connects single-chain antibody that VH gene and VL gene form, be made up of with non covalent bond be combined into Fv fragment antibody, by VH or functional domain of VL VH and VL, the atom that constitutes by single CDR etc.(4) multivalence miniantibody.Mainly contain double-stranded antibody, (ScFv)
2, Flex miniantibody, LD miniantibody, F (ab ')
2, F (ab '), (ScFv) etc.(5) bi-specific antibody.Be the antibody that a class has dual specificity and dual-use function, claim bifunctional antibody again.(6) recombinant antibody fusion proteins.Gene fragments such as Fab or Fv, with having that other protein genes such as the toxin of non-antibody or enzyme are connected to form a kind of recombinant protein of specific biological activity guiding target site.(7) phage antibody.The V district gene of Ig is connected after transfecting host bacterium with last gene III of filobactivirus DNA or gene VIII, makes its fusion protein product at film surface outer casing protein expression Fab or ScFv.By this product is taken turns the affine absorption of related antigen more, therefrom wash in a pan and sift out required specific antibody.
With above-mentioned antibody or by the polypeptide deutero-antibody of its genes encoding is carrier, and crosslinked immune conjugate of the effector substance of various anti-appositions and forming or guiding prodrug mainly contain following several form: (1) antibody-matrix conditioning agent conjugate.The deposition that the matrix conditioning agent can be regulated extracellular matrix has separately obtained curative effect preferably with degraded.But owing to after in its input body part arrival effect target site is only arranged, its regulating effect is not in full use and toxic side effect.With matrix conditioning agent and monoclonal antibody coupling, carry it by monoclonal antibody and arrive the effect that target site is given full play to its matrix degradation, make the effect of these factors stronger, and more single-minded.(2) antibody targeted enzymolysis prodrug.The conjugate of antibody and drug specificity activating enzymes is injected in the body, inject prodrug behind the certain hour at interval, make it change into the medicine that high density has degrading activity at the fibrosis position, thus the matrix of degradation of cell external sediment fast and effeciently.(3) immunoliposome.The surface energy that MAb is coupled to liposome fully combines the characteristic of MAb and antigen-specific bonded guidance quality and lipid physical efficiency parcel high amount of drug together, and relevant medicine in the embedding then can improve drug targeting and curative effect again.
3, the extracorporeal biology functional experiment of monoclonal antibody HAb18Gedomab1.
The experiment of gelatin zymogram: people's stellate cell (HSCs-T6) is cultured to logarithmic phase, uses 0.25% trysinization, with 10
5The density in/hole is inoculated in 96 orifice plates, cultivates 24h.Discard culture supernatant, change serum-free medium.Adding final concentration is the monoclonal antibody HAb18Gedomab1 of 100 μ g/ml.And set up negative control hole.10,20h collects the serum-free culture cell conditioned medium respectively.With the gelatin is 8% separation gel and the 5% concentrated glue of substrate preparation certain volume, gets culture supernatant and sample buffer mixture, and last sample begins electrophoresis.After electrophoresis stops, glue is put into Triton X-100 solution renaturation, in the gelatinase incubation buffer, hatch.Dyeing, decolouring, observation, film making.Experimental result, referring to accompanying drawing 6,1 negative contrast (10h) among the figure, 2 is HAb18Gedomab1 (10h), 3 negative contrasts (20h), 4 is HAb18Gedomab1 (20h).
The experiment of type i collagen zymogram: method is the same, and only changing substrate is type i collagen.Experimental result is referring to accompanying drawing 7,1 negative contrast (10h) among the figure, and 2 is HAb18Gedomab1 (10h), 3 negative contrasts (20h), 4 is HAb18Gedomab1 (20h).
Reconstituted basement membrane degradation experiment: on Millicell cell inner membrance, add Matrigel glue, put to glue dried.With 2.5g/L trysinization HSC cell, centrifuge washing.Hang with the RPIM-1640 that contains 0.1%BSA, chamber in the adding, adding final concentration in last chamber simultaneously is the monoclonal antibody HAb18Gedomab1 of 100 μ g/ml.In 24 orifice plates of the following chamber of cell, add 500 μ l chemoattractants.24 orifice plates are put into 37 ℃, cultivate 20h in the 5%CO2 incubator.Take out cell, discard nutrient solution, 95% ethanol is 25min fixedly, filter membrane HE dyeing, and gradient alcohol dehydration is wiped Matrigel glue and cell in the chamber, cutting-out filter membrane with cotton swab; Transparent back mounting.The cell count of counting film back side invasion and attack is counted 4 visuals field on the film at random under 40 * light microscopic, and its mean value is obtained in 3 parts of every cell countings, and test repeats 3 times.Experimental result is referring to accompanying drawing 8,1 negative contrast among the figure, and 2 is HAb18Gedomab1.
To sum up, gelatin zymogram experimental result shows that HAb18Gedomab1 antibody can promote the generation of MMP-2, MMP-9; Type i collagen zymogram experimental result shows that HAb18Gedomab1 antibody can promote the generation of MMP-1, MMP-8; The reconstituted basement membrane degradation experiment detects and to show, HAb18Gedomab1 acts on the degraded that can promote basilar membrane behind the HSC.These presentation of results, HAb18Gedomab1 monoclonal antibody have the potentiality that reverse apposition relative diseases such as hepatic fibrosis.
Sequence table
＜110〉Chen Zhinan
＜120〉light, the heavy chain variable region gene of HAb18Gedomab1 monoclonal antibody and its, coded polypeptide and application
<160>4
<210>1
<211>336
<212>DNA
＜213〉mouse
<220>
<221>V_region
<222>(1)...(336)
<400>1
gaa?gtg?aag?ctt?gag?gag?tct?gga?gga?ggc?ttg?gtg?caa?cct?gga?gga 48
tcc?atg?aaa?ctc?tcc?tgt?gtt?gcc?tct?gga?ttc?act?ttc?agt?aac?tac 96
tgg?atg?cac?tgg?gtc?cgc?cag?tct?cca?gag?aag?ggg?ctt?gag?tgg?gtt?144
gct?gaa?att?aga?ttg?aaa?tct?att?aat?tat?gca?aca?cat?tat?gcg?gag?192
tct?gtg?aaa?ggg?agg?ttc?acc?atc?tca?aga?gat?gat?tcc?aaa?agt?agt?240
gtc?tac?ctg?caa?atg?aac?aac?tta?aga?act?gaa?gac?act?ggc?att?tat?288
tac?tgt?acc?agt?tat?gat?tac?gaa?tac?tgg?ggc?caa?ggg?act?ctg?atc?336
<210>2
<211>324
<212>DNA
＜213〉mouse
<220>
<221>V_region
<222>(1)...(324)
<400>2
aac?att?gta?atg?acc?caa?tct?ccc?aaa?tcc?atg?tcc?atg?tca?gta?gga 48
gag?agg?gtc?acc?ttg?agc?tgc?aag?gcc?agt?gag?att?gtg?ggt?act?tat 96
gta?tcc?tgg?tat?caa?cag?aaa?cca?gaa?cag?tct?cct?aaa?ctg?ctg?ata?144
tac?ggg?gca?tcc?aac?cgg?tac?act?ggg?gtc?ccc?gat?cgc?ttc?aca?ggc?192
agt?gga?tct?gca?aca?gat?ttc?act?ctg?acc?atc?agc?agt?gtg?cag?gct?240
gaa?gac?ctt?gca?gat?tat?cac?tgt?gga?cag?agt?tac?agc?tat?cca?ttc?288
acg?ttc?ggc?tcg?ggg?aca?aag?ttg?gaa?ata?aaa?cgg?324
<210>3
<211>112
<212>PRT
＜213〉mouse
<220>
<221>V_segment
<400>3
1 5 10 15
Glu?Val?Lys?Leu?Glu?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro?Gly
20 25 30
Gly?Ser?Met?Lys?Leu?Ser?Cys?Val?Ala?Ser?Gly?Phe?Thr?Phe?Ser
35 40 45
Asn?Tyr?Trp?Met?His?Trp?Val?Arg?Gln?Ser?Pro?Glu?Lys?Gly?Leu
50 55 60
Glu?Trp?Val?Ala?Glu?Ile?Arg?Leu?Lys?Ser?Ile?Asn?Tyr?Ala?Thr
65 70 75
His?Tyr?Ala?Glu?Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp
80 85 90
Asp?Ser?Lys?Ser?Ser?Val?Tyr?Leu?Gln?Met?Asn?Asn?Leu?Arg?Thr
95 100 105
Glu?Asp?Thr?Gly?Ile?Tyr?Tyr?Cys?Thr?Ser?Tyr?Asp?Tyr?Glu?Tyr
110
Trp?Gly?Gln?Gly?Thr?Leu?Ile
<210>4
<211>108
<212>PRT
＜213〉mouse
<220>
<221>V_segment
<400>4
1 5 10 15
Asn?Ile?Val?Met?Thr?Gln?Ser?Pro?Lys?Ser?Met?Ser?Met?Ser?Val
20 25 30
Gly?Glu?Arg?Val?Thr?Leu?Ser?Cys?Lys?Ala?Ser?Glu?Ile?Val?Gly
35 40 45
Thr?Tyr?Val?Ser?Trp?Tyr?Gln?Gln?Lys?Pro?Glu?Gln?Ser?Pro?Lys
50 55 60
Leu?Leu?Ile?Tyr?Gly?Ala?Ser?Asn?Arg?Tyr?Thr?Gly?Val?Pro?Asp
65 70 75
Arg?Phe?Thr?Gly?Ser?Gly?Ser?Ala?Thr?Asp?Phe?Thr?Leu?Thr?Ile
80 85 90
Ser?Ser?Val?Gln?Ala?Glu?Asp?Leu?Ala?Asp?Tyr?His?Cys?Gly?Gln
95 100 105
Ser?Tyr?Ser?Tyr?Pro?Phe?Thr?Phe?Gly?Ser?Gly?Thr?Lys?Leu?Glu
Ile?Lys?Arg
Claims (8)
1, the monoclonal antibody HAb18Gedomab1 of the anti-HAb18G/CD147 extracellular region protein of a strain, it is characterized in that with specific hybridoma cell strain HAb18Gedomab1 prepared behind the HAb18G/CD147 extracellular region protein immune mouse, its chromosome number is at 58-126, mode 104-126, secreted antibody subtype are IgG1.
2, the heavy chain variable region gene of the described monoclonal antibody HAb18Gedomab1 of claim 1, it has sequence table＜400〉1 sequence.
3, by the polypeptide product of claim 2 coded by said gene, it has sequence table＜400〉3 sequence.
4, the chain variable region gene of the described monoclonal antibody HAb18Gedomab1 of claim 1, it has sequence table＜400〉2 sequence.
5, by the polypeptide product of claim 4 coded by said gene, it has sequence table＜400〉4 sequence.
6, reverse the application for the treatment of liver fibrosis agent as preparation with described monoclonal antibody HAb18Gedomab1 or its recombinant protein or protein derivatives.
7, heavy chain variable region gene or its encoded polypeptides product with described monoclonal antibody HAb18Gedomab1 sets out, and reassembles into various forms of genetic engineering antibodies or antibody derivatives, reverses the application for the treatment of liver fibrosis agent as preparation.
8, chain variable region gene or its encoded polypeptides product with described monoclonal antibody HAb18Gedomab1 sets out, and reassembles into various forms of genetic engineering antibodies or antibody derivatives, reverses the application for the treatment of liver fibrosis agent as preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100788586A CN100480388C (en) | 2004-06-14 | 2004-09-09 | HAb18Gedomab 1 monoclonal antibody and light and heavy chain variable area genes, coding polypeptide and use |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410026231.6 | 2004-06-14 | ||
| CN20041002631.6 | 2004-06-14 | ||
| CN200410026231 | 2004-06-14 | ||
| CNB2004100788586A CN100480388C (en) | 2004-06-14 | 2004-09-09 | HAb18Gedomab 1 monoclonal antibody and light and heavy chain variable area genes, coding polypeptide and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1782077A true CN1782077A (en) | 2006-06-07 |
| CN100480388C CN100480388C (en) | 2009-04-22 |
Family
ID=36772690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100788586A Active CN100480388C (en) | 2004-06-14 | 2004-09-09 | HAb18Gedomab 1 monoclonal antibody and light and heavy chain variable area genes, coding polypeptide and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100480388C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100586960C (en) * | 2006-06-23 | 2010-02-03 | 陈志南 | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application |
| CN103204939A (en) * | 2013-01-05 | 2013-07-17 | 陈志南 | CD147-HAb18MAb compound crystal structure and application thereof |
| CN110642947A (en) * | 2019-08-27 | 2020-01-03 | 中国人民解放军第四军医大学 | Anti-human CD147 monoclonal antibody, expression vector, cell strain and application thereof |
| CN113549152A (en) * | 2021-07-22 | 2021-10-26 | 中国人民解放军空军军医大学 | Humanized antibody against BASIGIN and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166989A (en) * | 1997-07-11 | 1997-12-10 | 中国人民解放军第四军医大学 | Radio-immunity treatment agent of anti human hepatic cancer monoclone antibody HAb18 |
-
2004
- 2004-09-09 CN CNB2004100788586A patent/CN100480388C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100586960C (en) * | 2006-06-23 | 2010-02-03 | 陈志南 | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, and application |
| CN103204939A (en) * | 2013-01-05 | 2013-07-17 | 陈志南 | CD147-HAb18MAb compound crystal structure and application thereof |
| CN110642947A (en) * | 2019-08-27 | 2020-01-03 | 中国人民解放军第四军医大学 | Anti-human CD147 monoclonal antibody, expression vector, cell strain and application thereof |
| CN110642947B (en) * | 2019-08-27 | 2023-07-28 | 中国人民解放军第四军医大学 | Anti-human CD147 monoclonal antibody, expression vector, cell strain and application thereof |
| CN113549152A (en) * | 2021-07-22 | 2021-10-26 | 中国人民解放军空军军医大学 | Humanized antibody against BASIGIN and application thereof |
| CN113549152B (en) * | 2021-07-22 | 2023-06-20 | 中国人民解放军空军军医大学 | anti-BASIGIN humanized antibody and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100480388C (en) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230064544A1 (en) | Anti-ctla4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
| JP4494977B2 (en) | Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its IL-2 fusion protein | |
| WO2018036472A1 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| WO2018036473A1 (en) | Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| CN1259973C (en) | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist | |
| JP7262597B2 (en) | Bispecific antibodies and methods of making and using the same | |
| WO2018188612A1 (en) | Bispecific antibody capable of being combined with human cd19 or cd20 and human cd3, and applications thereof | |
| CN101054416A (en) | HAb18GC2 monoclonal antibody and its light and heavy chain variable area genes, coding polypeptide and use | |
| CN104093841A (en) | An IL-15 and IL-15R[alpha] SUSHI domain based immunocytokines | |
| CN1186445C (en) | Light chain or heavy chain variable region gene of human liver cancer monoclonal antibody HAb18 and its application | |
| JP2023106392A (en) | Cd3 antigen binding fragment and application thereof | |
| TW201942132A (en) | Bispecific antibody | |
| EP3101035B1 (en) | Bifunctional fusion protein, preparation method therefor, and use thereof | |
| JP2023542049A (en) | Interleukin-2 muteins and their uses | |
| CN1782077A (en) | HAb18Gedomab 1 monoclonal antibody and its light and heavy chain variable area genes, coding polypeptide and use | |
| CA2597754A1 (en) | Methods and uses of antibodies in the purification of interferon | |
| CN111944047A (en) | anti-BCMA humanized single-chain antibody and application thereof | |
| WO2022105872A1 (en) | Anti-tigit antibody or antigen-binding fragment thereof | |
| CN1142183C (en) | Anti-idiotype microantibody and its preparing process and application | |
| CN111848806B (en) | EGFR-CD3 bifunctional antibody and application thereof | |
| CN1775808A (en) | Anti CD19 engineered antibody for target conjugated lymphocyte, leuco cyte and its use | |
| CN1279058C (en) | Engineering antibody against CD44 for inducing leukemia cell differentation and necrosis | |
| US20230159652A1 (en) | Transferrin receptor 1 targeting for carcinogenesis prevention | |
| CN1829533A (en) | Antibodies and fusion proteins that include engineered constant regions | |
| CN116102655A (en) | PD-L1/PD-1 targeting antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160204 Address after: 710032 Changle West Road, Shaanxi, China, No. 169, No. Patentee after: The Fourth Military Medical University of the Chinese People's Liberation Army Address before: 710032 center of cell engineering, The Fourth Military Medical University, 17 West Changle Road, Xi'an, Shaanxi Patentee before: Chen Zhinan |